Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
An opinionated take on NEJM highlights for Q3 of 2025
By
Marc Herant
NEJM
Exercise with cancer: it’s about more than fitness
Retrospective obser…
Read more
It was bioengineering at its best: An opinionated take on NEJM highlights for Q2 of 2025
By
Marc Herant
NEJM
The first porcine kidney transplant (in a live recipient)
It’s been a …
Read more
Some very disappointing failures: An opinionated take on NEJM highlights for August and September 2022
By
Marc Herant
NEJM
Is Parkinson’s α-synuclein going to be as elusive a target as β-amyloi…
Read more
An opinionated take on NEJM highlights for May 2017
By
Marc Herant
NEJM
A hammer finds new nails (which happen to be eyeballs)
The insulin gro…
Read more
NEJM Highlights November 2015: systems biology, RSV progress, a first in diabetes, hypertension goals, the case of Maryland
By
Marc Herant
NEJM
Systems biology finally gets real: an unexpected use for a diabetes dr…
Read more
NEJM Highlights March 2015: Progress against Crohn’s, PCSK9 inhibitors coming through, comparative effectiveness for diabetic macular edema, Eric Lander encourages the FDA on genomic testing regulation
By
Marc Herant
NEJM
A promising agent for Crohn’s Disease, a miserable illness
Crohn’s is …
